338 related articles for article (PubMed ID: 21940695)
21. Botulinum toxin treatment of sialorrhea: comparing different therapeutic preparations.
Tan EK
Eur J Neurol; 2006 Feb; 13 Suppl 1():60-4. PubMed ID: 16417600
[TBL] [Abstract][Full Text] [Related]
22. Ultrasound-guided botulinum toxin injections for treatment of drooling.
Breheret R; Bizon A; Jeufroy C; Laccourreye L
Eur Ann Otorhinolaryngol Head Neck Dis; 2011 Nov; 128(5):224-9. PubMed ID: 21600865
[TBL] [Abstract][Full Text] [Related]
23. Use of botulinum neurotoxin A in uncontrolled salivation in children with cerebral palsy: a pilot study.
Tiigimäe-Saar J; Leibur E; Kolk A; Talvik I; Tamme T
Int J Oral Maxillofac Surg; 2012 Dec; 41(12):1540-5. PubMed ID: 23068112
[TBL] [Abstract][Full Text] [Related]
24. Surgical management of chronic sialorrhea in pediatric patients: 10-year experience from one tertiary care institution.
Formeister EJ; Dahl JP; Rose AS
Int J Pediatr Otorhinolaryngol; 2014 Aug; 78(8):1387-92. PubMed ID: 24974144
[TBL] [Abstract][Full Text] [Related]
25. Randomized trial of botulinum toxin injections into the salivary glands to reduce drooling in children with neurological disorders.
Reid SM; Johnstone BR; Westbury C; Rawicki B; Reddihough DS
Dev Med Child Neurol; 2008 Feb; 50(2):123-8. PubMed ID: 18201301
[TBL] [Abstract][Full Text] [Related]
26. Successful management of drooling with botulinum toxin A in neurologically disabled children.
Ellies M; Rohrbach-Volland S; Arglebe C; Wilken B; Laskawi R; Hanefeld F
Neuropediatrics; 2002 Dec; 33(6):327-30. PubMed ID: 12571790
[TBL] [Abstract][Full Text] [Related]
27. Intraparotid injection of botulinum toxin A as a treatment to control sialorrhea in children with cerebral palsy.
Savarese R; Diamond M; Elovic E; Millis SR
Am J Phys Med Rehabil; 2004 Apr; 83(4):304-11; quiz 312-4, 336. PubMed ID: 15024333
[TBL] [Abstract][Full Text] [Related]
28. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism.
Mancini F; Zangaglia R; Cristina S; Sommaruga MG; Martignoni E; Nappi G; Pacchetti C
Mov Disord; 2003 Jun; 18(6):685-8. PubMed ID: 12784273
[TBL] [Abstract][Full Text] [Related]
29. Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial.
Jongerius PH; van den Hoogen FJ; van Limbeek J; Gabreëls FJ; van Hulst K; Rotteveel JJ
Pediatrics; 2004 Sep; 114(3):620-7. PubMed ID: 15342830
[TBL] [Abstract][Full Text] [Related]
30. Botulinum toxin type A for control of drooling in Asian patients with cerebral palsy.
Lin YC; Shieh JY; Cheng ML; Yang PY
Neurology; 2008 Jan; 70(4):316-8. PubMed ID: 18209205
[No Abstract] [Full Text] [Related]
31. Botulinum toxin injections for chronic sialorrhoea in children are effective regardless of the degree of neurological dysfunction: A single tertiary institution experience.
Mahadevan M; Gruber M; Bilish D; Edwards K; Davies-Payne D; van der Meer G
Int J Pediatr Otorhinolaryngol; 2016 Sep; 88():142-5. PubMed ID: 27497402
[TBL] [Abstract][Full Text] [Related]
32. Quantitative reduction of saliva production with botulinum toxin type B injection into the salivary glands.
Turk-Gonzales M; Odderson IR
Neurorehabil Neural Repair; 2005 Mar; 19(1):58-61. PubMed ID: 15673844
[TBL] [Abstract][Full Text] [Related]
33. Botulinum toxin assessment, intervention and aftercare for paediatric and adult drooling: international consensus statement.
Reddihough D; Erasmus CE; Johnson H; McKellar GM; Jongerius PH;
Eur J Neurol; 2010 Aug; 17 Suppl 2():109-21. PubMed ID: 20633182
[TBL] [Abstract][Full Text] [Related]
34. Botulinum toxin type a injections to salivary glands: combination with single event multilevel chemoneurolysis in 2 children with severe spastic quadriplegic cerebral palsy.
Kim H; Lee Y; Weiner D; Kaye R; Cahill AM; Yudkoff M
Arch Phys Med Rehabil; 2006 Jan; 87(1):141-4. PubMed ID: 16401453
[TBL] [Abstract][Full Text] [Related]
35. Clinical study of botulinum-A toxin in the treatment of sialorrhea in children with cerebral palsy.
Suskind DL; Tilton A
Laryngoscope; 2002 Jan; 112(1):73-81. PubMed ID: 11802042
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial.
Chinnapongse R; Gullo K; Nemeth P; Zhang Y; Griggs L
Mov Disord; 2012 Feb; 27(2):219-26. PubMed ID: 21887710
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness and safety of botulinum toxin in comparison with surgery for drooling in paediatric patients with neurological disorders: a systematic review.
Silva JPS; Faria LV; Almeida RC; Medeiros YL; Guimarães LDA
Br J Oral Maxillofac Surg; 2022 Jun; 60(5):e691-e701. PubMed ID: 35227530
[TBL] [Abstract][Full Text] [Related]
38. Botulinum toxin versus submandibular duct relocation for severe drooling.
Scheffer AR; Erasmus C; VAN Hulst K; VAN Limbeek J; Rotteveel JJ; Jongerius PH; van den Hoogen FJ
Dev Med Child Neurol; 2010 Nov; 52(11):1038-42. PubMed ID: 20561006
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and duration of botulinum toxin treatment for drooling in 131 children.
Scheffer AR; Erasmus C; van Hulst K; van Limbeek J; Jongerius PH; van den Hoogen FJ
Arch Otolaryngol Head Neck Surg; 2010 Sep; 136(9):873-7. PubMed ID: 20855679
[TBL] [Abstract][Full Text] [Related]
40. Onabotulinum toxin A for the treatment of sialorrhea in familial dysautonomia.
Daniel SJ; Cardona I
Int J Pediatr Otorhinolaryngol; 2014 May; 78(5):879-81. PubMed ID: 24725647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
